Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEMJA for Bilateral Limbal Stem Cell Deficiency
NCT03949881Phase 2Recruiting
- Sponsor
- Hospices Civils de Lyon
- Start
- Nov 2020
- Primary completion
- May 2031
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cultured autologous oral mucosa epithelial sheet in limbal stem cell deficiency (LSCD), sponsored by Hospices Civils de Lyon. Primary endpoint: Number of patients with any improvement in visual acuity at 24 months. Started Nov 2020; status: recruiting.
02
Drugs
cultured autologous oral mucosa epithelial sheet
03
Conditions
limbal stem cell deficiency (LSCD)
Beyond the preview
Go deeper on NCT03949881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03949881.